Stockreport
Jim Cramer Says “I Got to Reopen the File on Biogen” [Yahoo! Finance]
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Well, I read the upgrade today by Wells Fargo, and it talked about a bunch of revenue streams. including Alzheimer's, and it was very impressive. I actually said, you know what? I got to reopen the file on Biogen. It looks pretty… good. I also like Gilead, for that matter. Photo by Anna Nekrashevich on Pexels Biogen Inc. (NASDAQ:BIIB) develops therapies for serious neurological and autoimmune conditions, including multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Patient Capital Management stated the following regarding Biogen Inc. (NASDAQ:BIIB) in its fourth quarter 2025 investor letter This quarter we entered three new positions and exited one position. We increased our exposure to Biogen Inc. (NASDAQ:BIIB) in the quarter by buying long-dated call options expiring in 2028 with a strike price of $150. We continue to think Biogen is an attractive asset over the long term. The company has a number of late-stage pipeline assets that should reach the market ove
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BIIB | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BIIB alerts
BIIB alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
NEWS
NEWS
- Biogen (BIIB) had its price target raised by Rothschild & Co Redburn from $150.00 to $180.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Biogen (BIIB) had its price target raised by JPMorgan Chase & Co. from $175.00 to $185.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Biogen (BIIB) was upgraded by UBS Group AG from "neutral" to "buy". They now have a $225.00 price target on the stock.[MarketBeat]
- Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio [Yahoo! Finance][Yahoo! Finance]
- TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region [Yahoo! Finance][Yahoo! Finance]
- More
BIIB
SEC Filings
SEC Filings
- 4/6/26 - Form 8-K
- 4/3/26 - Form 4
- 3/31/26 - Form 8-K
- BIIB's page on the SEC website
- More